SCHEMBL1642029

SCHEMBL1642029

Cc1nc(-c2cccc(N)c2)c(-c2ccnc(Cl)n2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.48
CDK4 P11802 5/20 0.48
TSHR P16473 1/20 0.43
RECQL P46063 1/20 0.43
CCNE1 P24864 1/20 0.43
TGFBR1 P36897 1/20 0.42
CAMK2D Q13557 1/20 0.40
KARS1 Q15046 1/20 0.39
AURKA O14965 1/20 0.39
CDK1 P06493 1/20 0.39
CDK7 P50613 1/20 0.39
CDK9 P50750 1/20 0.39
MAPK14 Q16539 3/20 0.39
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
ROCK1 Q13464 2/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641824 0.88 TGFBR1 (0.55) TSHRRECQLTGFBR1CAMK2DMAPK14
SCHEMBL1127281 0.85 BRAF (0.51) CDK2CDK4TGFBR1CAMK2DBRAF
SCHEMBL1640578 0.81 CDK2 (0.53) CDK2CDK4CCNE1AURKACDK1
SCHEMBL1640422 0.80 CAMK2D (0.42) CDK2CDK4TSHRRECQLTGFBR1
SCHEMBL3422428 0.80 MAPK14 (0.48) CDK2CDK4MAPK14MAPT
SCHEMBL12490576 0.79 MAPK14 (0.60) CDK2CDK4TSHRRECQLTGFBR1
SCHEMBL1466904 0.78 CAMK2D (0.58) TSHRRECQLCAMK2DKARS1AURKA
SCHEMBL29039439 0.78 PTGS2 (0.51) CDK2TGFBR1
SCHEMBL30410597 0.78 PTGS2 (0.51) CDK2TGFBR1
SCHEMBL24761211 0.78 TGFBR1 (0.67) TGFBR1CAMK2DMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 CDK2 34/4885CDK4 40/4885TSHR 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.